Comparative Evaluation of the Efficacy and Tolerability of Chemotherapy in Patients with Drug-Resistant Pulmonary Tuberculosis Using Terizidone and Cycloserine in the Comprehensive Treatment
DOI:
https://doi.org/10.22141/2312-413x.4.09.2015.78840Keywords:
drug-resistant pulmonary tuberculosis, comprehensive treatment, terizidone, cycloserineAbstract
Introduction. Improving the efficiency of treatment of patients with drug-resistant pulmonary tuberculosis. Objective — to compare the efficacy and tolerability of chemotherapy in patients with drug-resistant pulmonary tuberculosis using terizidone and cycloserine in the intensive phase of comprehensive treatment. Materials and methods. Patients with drug-resistant pulmonary tuberculosis were divided into 3 groups. The first group consisted of 50 patients who received cycloserine. The second group included 79 patients who were treated with terizidone. The control group consisted of 87 patients in whom we applied the same chemotherapy regimens without the use of cycloserine and terizidone. Results. There was no significant difference in the effectiveness of treatment of patients with drug-resistant pulmonary tuberculosis between the chemotherapy regimens with inclusion in the combined treatment of tuberculosis drugs cycloserine and terizidone. Application of tuberculosis drugs cycloserine and terizidone in the intensive phase of comprehensive treatment increased the efficiency by 21.6 and 16.2 %, respectively. Conclusion. Tuberculosis drugs cycloserine and terizidone in the combination therapy of patients with drug-resistant pulmonary tuberculosis are clinically effective and well-tolerable, indicating the validity of their inclusion in chemotherapy regimens.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2016 O.M. Raznatovska, H.V. Khudiakov, A.H. Makarovych
This work is licensed under a Creative Commons Attribution 4.0 International License.